Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
Mais filtros

Base de dados
Tipo de documento
Intervalo de ano de publicação
1.
Int J Mol Sci ; 24(7)2023 Apr 06.
Artigo em Inglês | MEDLINE | ID: mdl-37047839

RESUMO

The deficiency of the gaseous molecule nitric oxide (NO) seems to be critically involved in the pathogenesis of schizophrenia. Thus, molecules that can normalize NO levels, as are NO donors, might be of utility for the medication of this psychiatric disease. The aim of the present study was to detect the ability of the NO donor molsidomine to reduce schizophrenia-like impairments produced by the blockade of the N-methyl-D-aspartate (NMDA) receptor in rats. Molsidomine's ability to attenuate social withdrawal and spatial recognition memory deficits induced by the NMDA receptor antagonist ketamine were assessed using the social interaction and the object location test, respectively. Further, the efficacy of the combination of sub-effective doses of molsidomine with sub-effective doses of the atypical antipsychotic clozapine in alleviating non-spatial recognition memory deficits was evaluated utilizing the object recognition task. Molsidomine (2 and 4 mg/kg) attenuated social withdrawal and spatial recognition memory deficits induced by ketamine. Co-administration of inactive doses of molsidomine (1 mg/kg) and clozapine (0.1 mg/kg) counteracted delay-dependent and ketamine-induced non-spatial recognition memory deficits. The current findings suggest that molsidomine is sensitive to glutamate hypofunction since it attenuated behavioral impairments in animal models mimicking the negative symptoms and cognitive deficits of schizophrenia. Additionally, the present results support the potential of molsidomine as an adjunctive drug for the therapy of schizophrenia.


Assuntos
Clozapina , Disfunção Cognitiva , Ketamina , Ratos , Animais , Doadores de Óxido Nítrico/farmacologia , Doadores de Óxido Nítrico/uso terapêutico , Molsidomina/efeitos adversos , Ketamina/efeitos adversos , Receptores de N-Metil-D-Aspartato , Óxido Nítrico/uso terapêutico , Ratos Wistar , Clozapina/efeitos adversos , Disfunção Cognitiva/tratamento farmacológico , Disfunção Cognitiva/etiologia , Transtornos da Memória/tratamento farmacológico , Isolamento Social , Cognição
2.
Psychopharmacology (Berl) ; 241(2): 341-350, 2024 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-37917180

RESUMO

RATIONALE: Several lines of evidence indicate that the neurosteroid dehydroepiandrosterone (DHEA) is involved in anxiety. BNN27 is a new DHEA derivative lacking steroidogenic effects. The beneficial effects exerted by BNN27 in preclinical models of schizophrenia and memory disorders have been recently reported. OBJECTIVES: The present study was designed to investigate the effects of this DHEA novel analog on anxiety-like behavior in rats. METHODS: To this end, the light/dark box, the open field, the contextual fear conditioning, and the excessive self-grooming induced by the serotonin 5-HT2c receptor agonist mCPP tests were utilized. RESULTS: Animals treated acutely with BNN27 (1, 3, and 6 mg/kg) dose dependently spent more time in the bright compartment of the light/dark box and in the central zone of the open field with respect to their vehicle-treated cohorts. Further, BNN27 reduced freezing behavior and weakened the mCPP-induced excessive self-grooming. CONCLUSIONS: Our data indicate that BNN27 is a highly potent anxiolytic agent, as in all studied paradigms it showed anxiolytic-like effects in male rats.


Assuntos
Ansiolíticos , Ansiedade , Ratos , Masculino , Animais , Ansiedade/tratamento farmacológico , Transtornos de Ansiedade/tratamento farmacológico , Ansiolíticos/farmacologia , Ansiolíticos/uso terapêutico , Desidroepiandrosterona/farmacologia
3.
PLoS One ; 18(7): e0288295, 2023.
Artigo em Inglês | MEDLINE | ID: mdl-37478122

RESUMO

Multiple Sclerosis (MS) is characterised by significant symptom diversity and complexity. The unpredictability of the symptoms and the emotional and cognitive facets of the disease have a significant impact on the patients' quality of life, relationships and other significant areas of living. Psychological interventions have been found to have moderate effects on quality of life, depression, stress reduction, improvement of wellbeing, anxiety, fatigue, sleep disturbances and emotion regulation. Most interventions so far are based on generic models of therapy which cannot always cover the complexity and unpredictability of MS. The present research project follows from an exploratory mixed method study on the experience of psychological interventions and the impact on the management of MS. The results of that study generated themes that led to the development of an integrative group psychological intervention named MyMS-Ally. The current study aims to explore the feasibility and acceptability of MyMS-Ally intervention and obtain preliminary data on the effects on quality of life, emotion regulation, depression and anxiety through the application of a convergent mixed methods design. People with MS will be recruited at the Bristol and Avon Multiple Sclerosis centre, North Bristol NHS Trust. They will participate in MyMS-Ally group intervention for 8 weeks. Individual semi-structured interviews drawing on Interpretative Phenomenological methodology will be conducted before and after the intervention and at three months follow up. Participants will complete quantitative measures on quality of life, emotion regulation, depression and anxiety before and after the intervention and at one and three months follow up. The aim is to explore the relevance, sustainability and adherence to the intervention and study processes (feasibility) as well as the appropriateness of the intervention based on the emotional and cognitive responses, satisfaction and perceived effectiveness (acceptability). It is aspired that this patient-centred psychological intervention will address needs and preferences of people with MS. The results of the present study will provide data for further development of the intervention and will lead to a big scale evaluation study.


Assuntos
Esclerose Múltipla , Humanos , Esclerose Múltipla/terapia , Esclerose Múltipla/psicologia , Intervenção Psicossocial , Qualidade de Vida , Estudos de Viabilidade , Ansiedade/terapia , Ansiedade/psicologia
4.
Psychol Psychother ; 85(3): 335-50, 2012 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-22903923

RESUMO

OBJECTIVES: Literature on termination originates mainly from clinical and theoretical accounts as well as practitioners' autobiographical reports. There is, however, a paucity of psychological research on termination. The purpose of this study is to examine the process of termination of therapy based on therapists' narratives of experiences of endings with patients. DESIGN: Grounded Theory methodology has been applied in this study in order to conceptualize the process of termination from the therapist's perspective. METHODS: Ten psychoanalytic and psychodynamic therapists were interviewed for this study. RESULTS: Grounded Theory analysis of the data revealed five central categories: therapist as a person, therapist's awareness of termination, development of therapeutic relationship, working through termination, and the aftermath (post-termination phase). CONCLUSIONS: The results offer a Grounded Theory model of the therapist's journey through termination of therapy with patients. Subcategories and their relationships will be explored. Implications for clinical practice, limitations and suggestions for further research will be discussed.


Assuntos
Atitude do Pessoal de Saúde , Relações Profissional-Paciente , Processos Psicoterapêuticos , Psicoterapia/métodos , Emoções , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Modelos Psicológicos , Apego ao Objeto , Terapia Psicanalítica/métodos , Teoria Psicológica , Pesquisa Qualitativa , Relações Pesquisador-Sujeito/psicologia
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA